Prostate specific antigen production by breast tumors after induction with oral contraceptives

Clinical Biochemistry

Volumn 31, Issue 4, 1998, Pages 285-288

  Katsaros, Dionyssios ^c   Melegos, Dimitrios N ^a   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; PREOPERATIVE CARE; PRIORITY JOURNAL;

AMERICAS; ANTIGENS; BIOLOGY; BREAST CANCER; CANADA; CANCER; CASE CONTROL STUDIES; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE METHODS; DEVELOPED COUNTRIES; DISEASES; FAMILY PLANNING; GENITALIA; GENITALIA, MALE; IMMUNITY; IMMUNOLOGIC FACTORS; NEOPLASMS; NORTH AMERICA; NORTHERN AMERICA; ORAL CONTRACEPTIVES; ORAL CONTRACEPTIVES, COMBINED; PHYSIOLOGY; PROSTATE; RESEARCH METHODOLOGY; RESEARCH REPORT; STUDIES; UROGENITAL SYSTEM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CONTRACEPTIVES, ORAL, SYNTHETIC; ETHINYL ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; PROGESTINS; PROSTATE-SPECIFIC ANTIGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 17444433174     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(97)00171-9     Document Type: Article

References (12)

1. 1. Diamandis EP, Yu H, Sutherland DJA. Detection of prostate specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994; 32: 301-10.
2. 2. Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP. Ultrasensitive detection of prostate specific antigen by a time-resolved immunofluorometric assay and the Immulite® Immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. Clin Chem 1996; 42: 675-84.
3. 3. Yu H, Giai M, Diamandis EP, et al. Prostate specific antigen is a new favourable prognostic indicator for women with breast cancer. Cancer Res 1995; 55: 2104-10.
4. 4. Yu H, Diamandis EP, Sutherland DJA. Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994; 27: 75-9.
5. 5. Yu H, Diamandis EP, Zarghami N, Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 1994; 32: 291-300.
6. 6. Zarghami N, Grass L, Diamandis EP. Steroid hormone regulation of prostate specific antigen gene expression in breast cancer. Br J Cancer 1997; 75: 579-88.
7. 7. Yu H, Diamandis EP, Monne M, Croce CM. Oral contraceptive-induced expression of prostate specific antigen in the female breast. J Biol Chem 1995; 270: 6615-18.
8. 8. Diamandis EP, Yu H. New biological functions of prostate specific antigen? J Clin Endocrinol Metab 1995; 80: 1515-17.
9. 9. Yu H, Diamandis EP, Levesque M, et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996; 40: 171-8.
10. 10. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. Prostate specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996; 271: 7043-51.
11. 11. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate specific antigen promoter. Mol Endocrinol 1997; 11: 148-61.
12. 12. Tsuyuki D, Grass L, Diamandis EP. Frequent detection of mutations in the 5′ flanking region of the prostate specific antigen gene in female breast cancer. Eur J Cancer 1997; 33: 1853-6.